3-chloro-5-((6-oxo-1-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-3-yl) methyl)-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile manufacturers
- Ulonivirine
-
- $1980.00
-
2026-07-27
- CAS:1591823-76-5
- Purity:
- Supply Ability: 10g
|
| | 3-chloro-5-((6-oxo-1-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-3-yl) methyl)-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile Basic information |
| Product Name: | 3-chloro-5-((6-oxo-1-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-3-yl) methyl)-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile | | Synonyms: | 3-chloro-5-((6-oxo-1-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-3-yl) methyl)-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile;Benzonitrile, 3-chloro-5-[[1-[[1,6-dihydro-6-oxo-5-(trifluoromethyl)-3-pyridazinyl]methyl]-1,6-dihydro-6-oxo-4-(trifluoromethyl)-5-pyrimidinyl]oxy]-;Ulonivirine (Synonyms: MK-8507);Ulonivirine/MK-8507;MK-8507;3-Chloro-5-((6-oxo-1-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-3-yl)methyl)-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile , Ulonivirine;Ulonivirine | | CAS: | 1591823-76-5 | | MF: | C18H8ClF6N5O3 | | MW: | 491.73 | | EINECS: | | | Product Categories: | | | Mol File: | 1591823-76-5.mol |  |
| | 3-chloro-5-((6-oxo-1-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-3-yl) methyl)-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile Chemical Properties |
| density | 1.65±0.1 g/cm3(Predicted) | | pka | 9.65±0.60(Predicted) | | form | Solid | | color | White to light yellow |
| | 3-chloro-5-((6-oxo-1-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-3-yl) methyl)-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile Usage And Synthesis |
| Uses | Ulonivirine (MK-8507) is an orally active non-nucleoside reverse transcriptase inhibitor with high antiviral activity. Ulonivirine can be used for the research of HIV-1 infection[1][2][3][4]. | | IC 50 | HIV-1 | | References | [1] Schürmann D, et al. Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week. J Acquir Immune Defic Syndr. 2022 Feb 1;89(2):191-198. DOI:10.1097/QAI.0000000000002834
[2] Gillespie SW, et al. Islatravir: evaluation of clinical development for HIV and HBV. Expert Opin Investig Drugs. 2024 Feb;33(2):85-93. DOI:10.1080/13543784.2024.2305130
[3] Ankrom W, et al. Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV. Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0093521. DOI:10.1128/AAC.00935-21
[4] Gillespie G, et al. Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK-8507, an Investigational, Oral, Once-Weekly Nonnucleoside Reverse Transcriptase Inhibitor. J Clin Pharmacol. 2022 Feb;62(2):199-205. DOI:10.1002/jcph.1957 |
| | 3-chloro-5-((6-oxo-1-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-3-yl) methyl)-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile Preparation Products And Raw materials |
|